Shares of Viking Therapeutics (VKTX) are down $2.70, or 6%, to $44.00 in pre-market trading following Merck (MRK) and Chinese biopharmaceutical company Hansoh Pharma’s announcement earlier that ...

Recognized for their exceptional products, Viking provides free standing ranges ... We paid for a high-end, professional appliance and expected it would last - this wine refrigerator internals ...

Create an account or log in to save stories. Pro Football Hall of Fame wide receiver Randy Moss said Friday he is being treated for cancer and is recovering from major surgery. In an appearance on ...

Barclays analyst Brandt Montour downgraded Viking Holdings (VIK) to Equal Weight from Overweight with an unchanged price target of $49. The firm cites the stock’s recent rally for the downgrade.